Endocrine Abstracts

Objectives: Alemtuzumab, a monoclonal antibody against CD52, is used in the treatment of multiple sclerosis. A side effect to the treatment is development of autoimmune thyroid disease. The aim was to evaluate the rate, type and course of thyroid disease in Danish patients with multiple sclerosis (MS) previously treated with Alemtuzumab.Methods: The study was a retrospective cohort study of patients treated with first series of alemtuzumab for multiple s...